Key Highlights
- The Biotech Growth Trust PLC (LSE:BIOG) fell 4.62% on 8 October 2026.
- US healthcare stocks opened weaker on Thursday, with large-cap biotech argenx down about 15% in pre-market trade.
- The pharmaceutical industry's main lobby group sued the US Department of Health and Human Services over most-favoured-nation drug pricing.
- Rising bond yields and Federal Reserve minutes pointing to another rate hike weighed on small and mid-cap biotech, where the trust has a tilt.
- The OrbiMed-managed trust delivered a one-year NAV total return of 85.5% to 31 July 2026, well ahead of its benchmark.
Biotech Growth Trust Slides With the Sector
Shares in The Biotech Growth Trust PLC (LSE:BIOG), the London-listed closed-end fund managed by specialist investor OrbiMed, fell 4.62% on Thursday 8 October 2026. The trust invests in biotechnology companies worldwide and measures itself against the Nasdaq Biotechnology index in sterling.
As a FTSE All-Share constituent with a focus on smaller, more innovative companies, LSE:BIOG tends to move more sharply than the broader healthcare sector. Thursday's fall reflected a combination of policy news, rate fears and weakness in US biotech shares.
Key Reasons Behind the 4.62% Drop
US biotech weakness was the immediate trigger. Healthcare stocks fell as US markets prepared to open, and argenx, one of the largest European biotech companies and a recent acquirer of a BIOG holding, dropped about 15% in pre-market trade. Because the trust's net asset value is driven mainly by US-listed shares, London traders marked the shares lower before Wall Street opened.
Drug pricing tensions escalated. PhRMA, the main US pharmaceutical lobby group, sued the Department of Health and Human Services and Secretary Robert F. Kennedy Jr. over most-favoured-nation pricing rules. The policy aims to tie US drug prices to the lowest prices paid in other developed countries. Separately, the US Department of Justice named violations of the Federal Food, Drug, and Cosmetic Act as an enforcement priority in its white-collar crackdown. Both developments raise uncertainty for drug developers.
Rates were the third factor. Federal Reserve minutes showed most officials expect another rate increase this year, and Treasury yields stayed near multi-decade highs. Early-stage biotech companies often burn cash for years before products reach market, so higher rates reduce the present value of their future profits and make fundraising harder. The shutdown of Caribou Biosciences after it failed to raise money for a pivotal trial highlighted that funding risk this week.
Why the Trust Is in Focus
The Biotech Growth Trust has been one of the best-performing Investment trusts of the past year. As at 31 July 2026, it delivered an NAV total return of 85.5% and a share price total return of 92.5% over one year, compared with 42.7% for its benchmark. In June alone, NAV rose 19.2% against an 11.4% benchmark gain, helped by clinical, regulatory and M&A news.
Takeovers have been a big driver. In July, argenx agreed to buy BIOG holding Forte Biosciences for $77 per share in cash, a 40.5% premium, valuing it at about $2.2 billion. Forte made up 3.03% of the trust's net Assets at the time. The trust's exposure includes antibody-drug conjugates, gene therapy, cell therapy, multispecific antibodies and oligonucleotide therapies, areas where large pharmaceutical companies have been active buyers.
Discount and Buyback Policy
Investors closely follow the gap between the share price and net asset value. The board aims to keep the discount from exceeding 6% in normal market conditions and buys back shares when it widens. In the year to 31 March 2026, the trust repurchased 7,183,277 shares at an average discount of 8.5%, at a cost of £69.5 million. Buybacks added 2.8% to NAV returns over that year. In early September, the discount sat close to 7%.
On volatile days, the share price can fall faster than the underlying portfolio, widening the discount and triggering further buybacks. This mechanism can help support the shares during sell-offs.
What Investors Are Watching
Key catalysts include US drug pricing policy, the outcome of the industry lawsuit, Interest Rate decisions and the pace of biotech M&A. Social Media discussion among UK investors has centred on whether the trust's strong run has priced in too much good news, or whether continued deal activity can extend gains.
For The Biotech Growth Trust PLC (LSE:BIOG), Volatility is part of the package. Its small-cap tilt and modest gearing magnify both rallies and pullbacks, and Thursday's 4.62% decline shows how quickly sentiment can shift.






Please wait processing your request...